Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC

• Published in: Molecular and cellular biochemistry 2024-09
• Main Authors: Shao, Wei-Qing, Li, Yi-Tong, Zhou, Xu, Zhang, Sheng-Guo, Fan, Ming-Hao, Zhang, Dong, Chen, Zhen-Mei, Yi, Chen-He, Wang, Sheng-Hao, Zhu, Wen-Wei, Lu, Ming, Chen, Ji-Song, Lin, Jing, Zhou, Yu
• Format: Article
• Language: English
• ISSN: 0300-8177; 1573-4919; 1573-4919
• DOI: 10.1007/s11010-024-05106-w

The degradation of proteasomes or lysosomes is emerging as a principal determinant of programmed death ligand 1 (PDL1) expression, which affects the efficacy of immunotherapy in various malignancies. Intracellular cholesterol plays a central role in maintaining the expression of membrane receptors; however, the specific effect of cholesterol on PDL1 expression in cancer cells remains poorly understood. Cholesterol starvation and stimulation were used to modulate the cellular cholesterol levels. Immunohistochemistry and western blotting were used to analyze the protein levels in the samples and cells. Quantitative real-time PCR, co-immunoprecipitation, and confocal co-localization assays were used for mechanistic investigation. A xenograft tumor model was constructed to verify these results in vivo. Our results showed that cholesterol suppressed the ubiquitination and degradation of PDL1 in hepatocellular carcinoma (HCC) cells. Further mechanistic studies revealed that the autocrine motility factor receptor (AMFR) is an E3 ligase that mediated the ubiquitination and degradation of PDL1, which was regulated by the cholesterol/p38 mitogenic activated protein kinase axis. Moreover, lowering cholesterol levels using statins improved the efficacy of programmed death 1 (PD1) inhibition in vivo. Our findings indicate that cholesterol serves as a signal to inhibit AMFR-mediated ubiquitination and degradation of PDL1 and suggest that lowering cholesterol by statins may be a promising combination strategy to improve the efficiency of PD1 inhibition in HCC.